Muphoran (Fotemustine)

Fotemustine belongs to the nitrosourea class of alkylating agents. It binds to DNA, forming cross‑links that prevent replication and transcription, ultimately leading to programmed cell death (apoptosis) of rapidly dividing tumor cells.

The dosage of Fotemustine is individualized by the treating physician based on factors such as tumor type, patient weight, organ function, and prior therapies. Prescribers determine the appropriate dose and schedule according to clinical guidelines.

Fotemustine is classified as contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential should use effective contraception. Breastfeeding is not recommended while receiving Fotemustine, as the drug may be excreted in milk and affect the infant.

To request Muphoran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Fotemustine shares the same alkylating mechanism as other nitrosoureas like carmustine and lomustine, but it is formulated for intravenous administration, allowing more controlled dosing. Its toxicity profile is similar, though some clinicians consider its pharmacokinetics to provide a slightly different therapeutic window.

Muphoran should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. Do not freeze the product, and keep it in the original packaging until ready for reconstitution and intravenous administration.

Muphoran is supplied as a sterile lyophilized powder for reconstitution. After proper preparation, it is administered intravenously by a qualified healthcare professional, typically as an infusion over a specified period according to the prescribing oncologist’s protocol.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, pulmonary fibrosis, and hepatic toxicity. Patients should be monitored closely for signs of infection, respiratory difficulty, and liver dysfunction, and treatment should be adjusted or discontinued if these events occur.

Fotemustine is contraindicated in patients with known hypersensitivity to nitrosoureas, those with severe bone‑marrow failure, uncontrolled liver disease, or active pulmonary fibrosis. It should also be avoided in pregnant women and in individuals who cannot adhere to required monitoring protocols.